Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 6/20 | 0.68 |
| ▸ | DRD3 | P35462 | 6/20 | 0.68 |
| ▸ | DRD2 | P14416 | 5/20 | 0.68 |
| ▸ | DRD4 | P21917 | 4/20 | 0.68 |
| ▸ | DRD5 | P21918 | 4/20 | 0.68 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193190 | 0.87 | DRD1 (0.70) | DRD1DRD3DRD2DRD4DRD5 | |
| SCHEMBL788875 | 0.83 | DRD1 (0.66) | DRD1DRD3DRD2DRD4DRD5 | |
| SCHEMBL11923826 | 0.80 | — | — | |
| SCHEMBL13266265 | 0.76 | DRD1 (0.50) | DRD1DRD3DRD2DRD4DRD5 | |
| SCHEMBL17461308 | 0.75 | DRD1 (0.44) | DRD1DRD3DRD2DRD4DRD5 | |
| SCHEMBL13068644 | 0.75 | DRD1 (0.44) | DRD1DRD3DRD2DRD4DRD5 | |
| SCHEMBL22379866 | 0.75 | DRD1 (0.45) | DRD1DRD3DRD2DRD4DRD5 | |
| SCHEMBL4710279 | 0.75 | PNMT (0.46) | DRD1DRD3DRD2DRD4DRD5 | |
| SCHEMBL10232765 | 0.75 | DRD1 (0.45) | DRD1DRD3DRD2DRD4DRD5 | |
| SCHEMBL18723736 | 0.73 | DRD3 (0.50) | DRD1DRD3DRD2DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111491918-B | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2023-10-24 | — | — | CN | claimed |
| WO-2025045145-A1 | WRN HELICASE-INHIBITING BIS-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 广州科恩泰生物医药科技有限公司 | 2025-03-06 | — | — | WO | disclosed |
| CN-119528909-A | Bisheterocyclic derivative for inhibiting WRN helicase, pharmaceutical composition containing bisheterocyclic derivative and application of bisheterocyclic derivative | 上海科恩泰生物医药科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| CN-111491918-B | Aryl and heteroaryl substituted indole compounds | 百时美施贵宝公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4159736-A1 | NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Longwood Biopharmaceuticals Co., Ltd. (CN) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023036140-A1 | 3CLPRO PROTEASE INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2023-03-16 | — | — | WO | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20060004009-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1589970-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO [2,3-C]PYRIDINE DERITIVES AND USE THEREOF | Rimonyx Pharmaceuticals Ltd. (IL) | 2005-11-02 | — | — | EP | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004069149-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING THIENO[2,3-C]PYRIDINE DERIVATIVES AND USE THEREOF | RIMONYX PHARMACEUTICALS LTD. (IL) | 2004-08-19 | — | — | WO | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-0314154-A2 | Tetrahydrofuro- and thieno(2,3-c)pyridines, their use as a medicament and process for their preparation | BOEHRINGER INGELHEIM KG (DE) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004009-A1 | Ethylenediamine derivatives | F2, ECE1, MLLT1 | DRD1 496/4885DRD3 713/4885DRD2 702/4885 |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | DRD1 4870/4885DRD3 4855/4885DRD2 4864/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | DRD1 4744/4885DRD3 4684/4885DRD2 4661/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | DRD1 281/4885DRD3 283/4885DRD2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.